At the bedside: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer

Journal of Leukocyte Biology

Volumn 96, Issue 2, 2014, Pages 213-224

  Dalal, Rahul S ^a   Moss, Steven F ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Chemoprevention; Eradication therapy; Gastric carcinogenesis; Intestinal metaplasia; Single nucleotide polymorphisms

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

BASIC RESEARCH; CANCER GROWTH; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE ERADICATION; DNA DAMAGE; GENE CLUSTER; GENE CONTROL; GENETIC SUSCEPTIBILITY; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; PATHOGENESIS; POLYAMINE METABOLISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; STOMACH CARCINOGENESIS;

CHEMOPREVENTION; ERADICATION THERAPY; GASTRIC CARCINOGENESIS; INTESTINAL METAPLASIA; SINGLE NUCLEOTIDE POLYMORPHISMS;

DNA DAMAGE; GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS;

EID: 84905008577     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.4BT0214-100R     Document Type: Review

References (128)

1. McColl, K. E. (2010) Clinical practice. Helicobacter pylori infection. N. Engl. J. Med. 362, 1597-1604.
2. Parkin, D. M. (2006) The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044.
3. National Cancer Institute and the National Institutes of Health. Stomach (gastric) cancer. Retrieved January 2, 2014, from http://www. Cancer. gov/cancertopics/types/stomach/.
4. De Martel, C., Ferlay, J., Franceschi, S., Vignat, J., Bray, F., Forman, D., Plummer, M. (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13, 607-615.
5. Ross, J. R., Griffin, B. G., Jordan, S. M. (1952) Gastritis and its sequelae. Gastroenterology 22, 205-213.
6. Correa, P., Haenszel, W., Cuello, C., Tannenbaum, S., Archer, M. (1975) A model for gastric cancer epidemiology. Lancet 2, 58-60.
7. Moss, S. F., Blaser, M. J. (2005) Mechanisms of disease: inflammation and the origins of cancer. Nat. Clin. Pract. Oncol. 2, 90-107.
8. Moran, A. P., Lindner, B., Walsh, E. J. (1997) Structural characterization of the lipid A component of Helicobacter pylori rough-and smoothform lipopolysaccharides. J. Bacteriol. 179, 6453-6463.
9. Gewirtz, A. T., Yu, Y., Krishna, U. S., Israel, D. A., Lyons, S. L., Peek R. M., Jr., (2004) Helicobacter pylori flagellin evades Toll-like receptor 5-mediated innate immunity. J. Infect. Dis. 189, 1914-1920.
10. Cover, T. L., Blaser, M. J. (1992) Purification and characterization of the vacuolating toxin from Helicobacter pylori. J. Biol. Chem. 267, 10570-10575.
11. Gebert, B., Fischer, W., Weiss, E., Hoffmann, R., Haas, R. (2003) Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 301, 1099-1102.
12. Kandulski, A., Wex, T., Kuester, D., Peitz, U., Gebert, I., Roessner, A., Malfertheiner, P. (2008) Naturally occurring regulatory T-cells (CD4+, CD25high, FOXP3+) in the antrum and cardia are associated with higher H. pylori colonization and increased gene expression of TGF-β1. Helicobacter 13, 295-303.
13. Kindlund, B., Sjöling, A., Hansson, M., Edebo, A., Hansson, L. E., Sjövall, H., Svennerholm, A. M., Lundin, B. S. (2009) FOXP3+ expressing CD4(+) T-cell numbers increase in areas of duodenal gastric metaplasia and are associated with CD4(+) T-cell aggregates in the duodenum of Helicobacter pylori-infected duodenal ulcer patients. Helicobacter 14, 192-201.
14. Cook, K. W., Letley, D. P., Ingram, R. J., Staples, E., Skjoldmose, H., Atherton, J. C., Robinson, K. (2014) CCL20/CCR6-mediated migration of regulatory T cells to the Helicobacter pylori-infected human gastric mucosa. Gut doi: 10. 1136/gutjnl-2013-306253 [Epub ahead of print].
15. Lundgren, A., Suri-Payer, E., Enarsson, K., Svennerholm, A. M., Lundin, B. S. (2003) Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect. Immun. 71, 1755-1762.
16. Jang, T. J. (2010) The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer. Pathol. Res. Pract. 206, 34-38.
17. Wolf, A. M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., Grubeck-Loebenstein, B. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606-612.
18. Islami, F., Kamangar, F. (2008) Helicobacter pylori and esophageal cancer risk: a meta-analysis. Cancer Prev. Res. (Phila) 1, 329-338.
19. Dellon, E. S., Peery, A. F., Shaheen, N. J., Morgan, D. R., Hurrell, J. M., Lash, R. H., Genta, R. M. (2011) Inverse association of esophageal eosinophilia with Helicobacter pylori based on analysis of a US pathology database. Gastroenterology 141, 1586-1592.
20. Chen, Y., Blaser, M. J. (2007) Inverse associations of Helicobacter pylori with asthma and allergy. Arch. Intern. Med. 167, 821-827.
21. Lebwohl, B., Blaser, M. J., Ludvigsson, J. F., Green, P. H., Rundle, A., Sonnenberg, A., Genta, R. M. (2013) Decreased risk of celiac disease in patients with Helicobacter pylori colonization. Am. J. Epidemiol. 178, 1721-1730.
22. Luther, J., Dave, M., Higgins, P. D., Kao, J. Y. (2010) Association between Helicobacter pylori infection and inflammatory bowel disease: a meta-analysis and systematic review of the literature. Inflamm. Bowel Dis. 16, 1077-1084.
23. Oertli, M., Müller, A. (2012) Helicobacter pylori targets dendritic cells to induce immune tolerance, promote persistence and confer protection against allergic asthma. Gut Microbes 3, 566-571.
24. Arnold, I. C., Dehzad, N., Reuter, S., Martin, H., Becher, B., Taube, C., Müller, A. (2011) Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells. J. Clin. Invest. 121, 3088-3093.
25. Smith, G., Hold, G. L., Tahara, E., El-Omar, E. M. (2006) Cellular and molecular aspects of gastric cancer. World J. Gastroenterol. 12, 2979-2990.
26. Correa, P., Piazuelo, M. B. (2012) The gastric precancerous cascade. J. Dig. Dis. 13, 2-9.
27. Persson, C., Canedo, P., Machado, J. C., El-Omar, E. M., Forman, D. (2011) Polymorphisms in inflammatory response genes and their association with gastric cancer: a HuGE systematic review and meta-analyses. Am. J. Epidemiol. 173, 259-270.
28. Segal, E. D., Lange, C., Covacci, A., Tompkins, L. S., Falkow, S. (1997) Induction of host signal transduction pathways by Helicobacter pylori. Proc. Natl. Acad. Sci. USA 94, 7595-7599.
29. Su, B., Ceponis, P. J., Lebel, S., Huynh, H., Sherman, P. M. (2003) Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells. Infect. Immun. 71, 3496-3502.
30. Salama, N. R., Hartung, M. L., Müller, A. (2013) Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori. Nat. Rev. Microbiol. 11, 385-399.
31. Castaño-Rodríguez, N., Kaakoush, N. O., Goh, K. L., Fock, K. M., Mitchell, H. M. (2013) The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and metaanalysis. PLoS One 8, e60327.
32. Hold, G. L., Rabkin, C. S., Chow, W. H., Smith, M. G., Gammon, M. D., Risch, H. A., Vaughan, T. L., McColl, K. E., Lissowska, J., Zatonski, W., Schoenberg, J. B., Blot, W. J., Mowat, N. A., Fraumeni, J. F., El-Omar, E. M. (2007) A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 132, 905-912.
33. Santini, D., Angeletti, S., Ruzzo, A., Dicuonzo, G., Galluzzo, S., Vincenzi, B., Calvieri, A., Pizzagalli, F., Graziano, N., Ferraro, E., Lorino, G., Altomare, A., Magnani, M., Graziano, F., Tonini, G. (2008) Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin. Exp. Immunol. 154, 360-364.
34. Rosenstiel, P., Hellmig, S., Hampe, J., Ott, S., Till, A., Fischbach, W., Sahly, H., Lucius, R., Fölsch, U. R., Philpott, D., Schreiber, S. (2006) Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cell. Microbiol. 8, 1188-1198.
35. Kumar, H., Kawai, T., Akira, S. (2011) Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16-34.
36. Companioni, O., Bonet, C., Muñoz, X., Weiderpass, E., Panico, S., Tumino, R., Palli, D., Agnoli, C., Paolo, V., Boutron-Ruault, M. C., et al. (2014) Polymorphisms of Helicobacter pylori signaling pathway genes and gastric cancer risk in the European Prospective Investigation into Cancer-Eurgast cohort. Int. J. Cancer 134, 92-101.
37. Hnatyszyn, A., Szalata, M., Stanczyk, J., Cichy, W., Slomski, R. (2010) Association of c. 802C> T polymorphism of NOD2/CARD15 gene with the chronic gastritis and predisposition to cancer in H. pylori infected patients. Exp. Mol. Pathol. 88, 388-393.
38. Baccarelli, A., Hou, L., Chen, J., Lissowska, J., El-Omar, E. M., Grillo, P., Giacomini, S. M., Yaeger, M., Bernig, T., Zatonski, W., Fraumeni J. F., Jr., Chanock, S. J., Chow, W. H. (2006) Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int. J. Cancer 119, 1970-1975.
39. El-Omar, E. M. (2001) The importance of interleukin 1β in Helicobacter pylori associated disease. Gut 48, 743-747.
40. Robert, A., Olafsson, A. S., Lancaster, C., Zhang, W. R. (1991) Interleukin-1 is cytoprotective, antisecretory, stimulates PGE2 synthesis by the stomach, and retards gastric emptying. Life Sci. 48, 123-134.
41. El-Omar, E. M., Carrington, M., Chow, W. H., McColl, K. E., Bream, J. H., Young, H. A., Herrera, J., Lissowska, J., Yuan, C. C., Rothman, N., Lanyon, G., Martin, M., Fraumeni J. F., Jr., Rabkin, C. S. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404, 398-402.
42. El-Omar, E. M., Rabkin, C. S., Gammon, M. D., Vaughan, T. L., Risch, H. A., Schoenberg, J. B., Stanford, J. L., Mayne, S. T., Goedert, J., Blot, W. J., Fraumeni J. F., Jr., Chow, W. H. (2003) Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124, 1193-1201.
43. Xue, H., Lin, B., Ni, P., Xu, H., Huang, G. (2010) Interleukin-1B and interleukin-1 RN polymorphisms and gastric carcinoma risk: a metaanalysis. J. Gastroenterol. Hepatol. 25, 1604-1617.
44. Figueiredo, C., Machado, J. C., Pharoah, P., Seruca, R., Sousa, S., Carvalho, R., Capelinha, A. F., Quint, W., Caldas, C., van Doom, L. J., Carneiro, F., Sobrinho-Simões, M. (2002) Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J. Natl. Cancer Inst. 94, 1680-1687.
45. Camargo, M. C., Mera, R., Correa, P., Peek R. M., Jr., Fontham, E. T., Goodman, K. J., Piazuelo, M. B., Sicinschi, L., Zabaleta, J., Schneider, B. G. (2006) Interleukin-1 β and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 15, 1674-1687.
46. Wang, P., Xia, H. H., Zhang, J. Y., Dai, L. P., Xu, X. Q., Wang, K. J. (2006) Association of interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis. Int. J. Cancer 120, 552-562.
47. Kamangar, F., Cheng, C., Abnet, C. C., Rabkin, C. S. (2006) Interleukin-1B polymorphisms and gastric cancer risk-a meta-analysis. Cancer Epidemiol. Biomarkers Prev. 15, 1920-1928.
48. Zeng, Z. R., Hu, P. J., Hu, S., Pang, R. P., Chen, M. H., Ng, M., Sung, J. J. (2003) Association of interleukin 1B gene polymorphism and gastric cancers in high and low prevalence regions in China. Gut 52, 1684-1689.
49. Shen, J., Arnett, D. K., Peacock, J. M., Parnell, L. D., Kraja, A., Hixson, J. E., Tsai, M. Y., Lai, C. Q., Kabagambe, E. K., Straka, R. J., Ordovas, J. M. (2007) Interleukin1β genetic polymorphisms interact with polyunsaturated fatty acids to modulate risk of the metabolic syndrome. J. Nutr. 137, 1846-1851.
50. Tu, S., Bhagat, G., Cui, G., Takaishi, S., Kurt-Jones, E. A., Rickman, B., Betz, K. S., Penz-Oesterreicher, M., Bjorkdahl, O., Fox, J. G., Wang, T. C. (2008) Overexpression of interleukin-1β induces gastric inflam-mation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14, 408-419.
51. Beales, I. L., Calam, J. (1998) Interleukin 1 β and tumour necrosis factor α inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 42, 227-234.
52. Gorouhi, F., Islami, F., Bahrami, H., Kamangar, F. (2008) Tumour-necrosis factor-A polymorphisms and gastric cancer risk: a meta-analysis. Br. J. Cancer 98, 1443-1451.
53. Lu, W., Pan, K., Zhang, L., Lin, D., Miao, X., You, W. (2005) Genetic polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor necrosis factor (+) and risk of gastric cancer in a Chinese population. Carcinogenesis 26, 631-636.
54. Lee, W. P., Tai, D. I., Lan, K. H., Li, A. F., Hsu, H. C., Lin, E. J., Lin, Y. P., Sheu, M. L., Li, C. P., Chang, F. Y., Chao, Y., Yen, S. H., Lee, W. P. (2005) The-251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin. Cancer Res. 11, 6431-6441.
55. Ohyauchi, M., Imatani, A., Yonechi, M., Asano, N., Miura, A., Iijima, K., Koike, T., Sekine, H., Ohara, S., Shimosegawa, T. (2005) The polymorphism interleukin 8-251A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 54, 330-335.
56. Wu, M. S., Wu, C. Y., Chen, C. J., Lin, M. T., Shun, C. T., Lin, J. T. (2003) Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int. J. Cancer 104, 617-623.
57. Smythies, L. E., Waites, K. B., Lindsey, J. R., Harris, P. R., Ghiara, P., Smith, P. D. (2000) Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL4, but not IFN-γ, gene-deficient mice. J. Immunol. 165, 1022-1029.
58. Thye, T., Burchard, G. D., Nilius, M., Müller-Myhsok, B., Horstmann, R. D. (2003) Genomewide linkage analysis identifies polymorphism in the human interferon-β receptor affecting Helicobacter pylori infection. Am. J. Hum. Genet. 72, 448-453.
59. Canedo, P., Corso, G., Pereira, F., Lunet, N., Suriano, G., Figueiredo, C., Pedrazzani, C., Moreira, H., Barros, H., Carneiro, F., Seruca, R., Roviello, F., Machado, J. C. (2008) The interferon γ receptor 1 (IFNGR1)-56C/T gene polymorphism is associated with increased risk of early gastric carcinoma. Gut 57, 1504-1508.
60. Hou, L., El Omar, E. M., Chen, J., Grillo, P., Rabkin, C. S., Baccarelli, A., Yeager, M., Chanock, S. J., Zatonski, W., Sobin, L. H., Lissowska, J., Fraumeni J. F., Jr., Chow, W. H. (2007) Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis 28, 118-123.
61. Mayerle, J., den Hoed, C. M., Schurmann, C., Stolk, L., Homuth, G., Peters, M. J., Capelle, L. G., Zimmermann, K., Rivadeneira, F., Gruska, S., Völzke, H., de Vries, A. C., Völker, U., Teumer, A., van Meurs, J. B., Steinmetz, I., Nauck, M., Ernst, F., Weiss, F. U., Hofman, A., Zenker, M., Kroemer, H. K., Prokisch, H., Uitterlinden, A. G., Lerch, M. M., Kuipers, E. J. (2013) Identification of genetic loci associated with Helicobacter pylori serologic status. JAMA 309, 1912-1920.
62. Li, M., Huang, L., Qiu, H., Fu, Q., Li, W., Yu, Q., Sun, L., Zhang, L., Hu, G., Hu, J., Yuan, X. (2013) Helicobacter pylori infection synergizes with three inflammation-related genetic variants in the GWASs to increase risk of gastric cancer in a Chinese population. PLoS One 8, e74976.
63. Rizzato, C., Kato, I., Plummer, M., Muñoz, N., Canzian, F. (2013) Genetic variation in PSCA and risk of gastric advanced preneoplastic lesions and cancer in relation to Helicobacter pylori infection. PLoS One 8, e73100.
64. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., Thun, M. J. (2008) Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96.
65. Leung, W. K., Wu, M. S., Kakugawa, Y., Kim, J. J., Yeoh, K. G., Goh, K. L., Wu, K. C., Sollano, J., Kachintorn, U., Gotoda, T., Lin, J. T., You, W. C., Ng, E. K., Sung, J. J., Asia Pacific Working Group on Gastric Cancer (2008) Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 9, 279-287.
66. Marshall, B. J., Warren, J. R. (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1, 1311-1315.
67. World Health Organization, International Agency for Research on Cancer (1994) IARC monographs on the evaluation of carcinogenic risks to humans, volume 61, schistosomes, liver flukes and Helicobacter pylori, summary of data reported and evaluation, Lyon, France.
68. Wu, C. Y., Kuo, K. N., Wu, M. S., Chen, Y. J., Wang, C. B., Lin, J. T. (2008) Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 137, 1641-1648.
69. Takenaka, R., Okada, H., Kato, J., Makidono, C., Hori, S., Kawahara, Y., Miyoshi, M., Yumoto, E., Imagawas, A., Toyokawa, T., Sakaguchi, K., Shiratori, Y. (2007) Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment. Pharmacol. Ther. 25, 805-812.
70. Ogura, K., Hirata, Y., Yanai, A., Shibata, W., Ohmae, T., Mitsuno, Y., Maeda, S., Watabe, H., Yamaji, Y., Okamoto, M., Yoshida, H., Kawabe, T., Omata, M. (2008) The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J. Clin. Gastroenterol. 42, 279-283.
71. Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., Schlemper, R. J. (2001) Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784-789.
72. Yanaoka, K., Oka, M., Ohata, H., Yoshimura, N., Deguchi, H., Mukoubayashi, C., Enomoto, S., Inoue, I., Iguchi, M., Maekita, T., Ueda, K., Utsunomiya, H., Tamai, H., Fujishiro, M., Iwane, M., Takeshita, T., Mohara, O., Ichinose, M. (2009) Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. Int. J. Cancer 125, 2697-2703.
73. Take, S., Mizuno, M., Ishiki, K., Yoshida, T., Ohara, N., Yokota, K., Oguma, K., Okada, H., Yamamoto, K. (2011) The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J. Gastroenterol. 46, 318-324.
74. Lee, Y. C., Chen, T. H., Chiu, H. M., Shun, C. T., Chiang, H., Liu, T. Y., Wu, M. S., Lin, J. T. (2013) The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 62, 676-682.
75. Fuccio, L., Zagari, R. M., Eusebi, L. H., Laterza, L., Cennamo, V., Ceroni, L., Grilli, D., Bazzoli, F. (2009) Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med. 151, 121e8; erratum in (2009) Ann. Intern. Med. 151, 516.
76. Wong, B. C., Lam, S. K., Wong, W. M., Chen, J. S., Zheng, T. T., Feng, R. E., Lai, K. C., Hu, W. H., Yuen, S. T., Leung, S. Y., Fong, D. Y., Ho, J., Ching, C. K., Chen, J. S., China Gastric Cancer Study Group (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291, 187-194.
77. You, W. C., Brown, L. M., Zhang, L., Li, J. Y., Jin, M. L., Chang, Y. S., Ma, J. L., Pan, K. F., Liu, W. D., Hu, Y., Crystal-Mansour, S., Pee, D., Blot, W. J., Fraumeni J. F., Jr., Xu, G. W., Gail, M. H. (2006) Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J. Natl. Cancer Inst. 98, 974-983.
78. Ma, J. L., Zhang, L., Brown, L. M., Li, J. Y., Shen, L., Pan, K. F., Liu, W. D., Hu, Y., Han, Z. X., Crystal-Mansour, S., Pee, D., Blot, W. J., Fraumeni J. F., Jr., You, W. C., Gail, M. H. (2012) Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J. Natl. Cancer Inst. 104, 488-492.
79. Mera, R., Fontham, E. T., Bravo, L. E., Bravo, J. C., Piazuelo, M. B., Camargo, M. C., Correa, P. (2005) Long term follow up of patients treated for Helicobacter pylori infection. Gut 54, 1536-1540.
80. Correa, P., Fontham, E. T., Bravo, J. C., Bravo, L. E., Ruiz, B., Zarama, G., Realpe, J. L., Malcolm, G. T., Li, D., Johnson, W. D., Mera, R. (2000) Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J. Natl. Cancer Inst. 92, 1881-1888.
81. Fukase, K., Kato, M., Kikuchi, S., Inoue, K., Uemura, N., Okamoto, S., Terao, S., Amagai, K., Hayashi, S., Asaka, M. iven-names>, Japan Gast Study Group. (2008) Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 372, 392-397.
82. Choi, J., Kim, S. G., Yoon, H., Im, J. P., Kim, J. S., Kim, W. H., Jung, H. C. (2014) Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin. Gastroenterol. Hepatol. 12, 793. e1-800. e1.
83. Maehata, Y., Nakamura, S., Fujisawa, K., Esaki, M., Moriyama, T., Asano, K., Fuyuno, Y., Yamaguchi, K., Egashira, I., Kim, H., Kanda, M., Hirahashi, M., Matsumoto, T. (2012) Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest. Endosc. 75, 39-46.
84. Bae, S. E., Jung, H. Y., Kang, J., Park, Y. S., Baek, S., Jung, J. H., Choi, J. Y., Kim, M. Y., Ahn, J. Y., Choi, K. S., Kim, D. H., Lee, J. H., Choi, K. D., Song, H. J., Lee, G. H., Kim, J. H. (2014) Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am. J. Gastroenterol. 109, 60-67.
85. Areia, M., Carvalho, R., Cadime, A. T., Rocha Goncalves, F., Dinis-Ribeiro, M. (2013) Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter 18, 325-337.
86. Ferlay, J., Shin, H. R., Bray Forman, D., Mathers, C., Parkin, D. M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917.
87. Asaka, M., Kato, M., Graham, D. (2010) Strategy for eliminating gastric cancer in Japan. Helicobacter 15, 486-490.
88. Asaka, M. (2013) A new approach for elimination of gastric cancer deaths in Japan. Int. J. Cancer 132, 1272-1276.
89. Wundisch, T., Dieckhoff, P., Greene, B., Thiede, C., Wilhelm, C., Stolte, M., Newbauer, A. (2012) Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology 143, 936-942.
90. Asaka, M., Kato, M., Sakamoto, N. (2014) Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J. Gastroenterol. 49, 1-8.
91. Dinis-Ribeiro, M., Areia, M., de Vries, A. C., Marcos-Pinto, R., Monteiro-Soares, M., O'Connor, A., Pereira, C., Pimentel-Nunes, P., Correia, R., Ensari, A., Dumonceau, J. M., Machado, J. C., Macedo, G., Malfertheiner, P., Matysiak-Budnik, T., Megraud, F., Miki, K., O'Morain, C., Peek, R. M., Ponchon, T., Ristimaki, A., Rembacken, B., Carneiro, F., Kuipers, E. J. (2012) Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 44, 74-94.
92. Correa, P., Piazuelo, M. B., Wilson, K. T. (2010) Pathology of gastric intestinal metaplasia: clinical implications. Am. J. Gastroenterol. 105, 493-508.
93. Inoue, M., Tsugane, S. (2005) Epidemiology of gastric cancer in Japan. Postgrad. Med. J. 81, 419-424.
94. American Gastroenterological Association, Spechler, S. J., Sharma, P., Souza, R. F., Inadomi, J. M., Shaheen, N. J. (2011) American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 140, 1084-1091.
95. Kargman, S., Charleson, S., Cartwright, M., Frank, J., Riendeau, D., Mancini, J., Evans, J., O'Neill, G. (1996) Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111, 445-454.
96. Sawaoka, H., Kawano, S., Tsuji, S., Tsuji, M., Sun, W., Gunawan, E. S., Hori, M. (1998) Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot. Essent. Fatty Acids 59, 313-316.
97. Ristimäki, A., Honkanen, N., Jänkälä, H., Sipponen, P., Härkönen, M. (1997) Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57, 1276-1280.
98. Lim, H. Y., Joo, H. J., Choi, J. H., Yi, J. W., Yang, M. S., Cho, D. Y., Kim, H. S., Nam, D. K., Lee, K. B., Kim, H. C. (2000) Increased expression of cyclo-oxygenase-2 protein in human gastric carcinoma. Clin. Cancer Res. 6, 519-525.
99. Song, J., Su, H., Zhou, Y. Y., Guo, L. L. (2014) Cyclooxygenase-2 expression is associated with poor overall survival of patients with gastric cancer: a meta-analysis. Dig. Dis. Sci. 59, 436-445.
100. Duan, L., Wu, A. H., Sullivan-Halley, J., Bernstein, L. (2008) Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol. Biomarkers. Prev. 17, 126-134.
101. Akre, K., Ekström, A. M., Signorello, L. B., Hansson, L. E., Nyrén, O. (2001) Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br. J. Cancer 84, 965-968.
102. Zaridze, D., Borisova, E., Maximovitch, D., Chkhikvadze, V. (1999) Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int. J. Cancer 82, 473-476.
103. Lindblad, M., Lagergren, J., Garcia Rodriguez, L. A. (2005) Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers. Prev. 14, 444-450.
104. Thun, M. J., Namboodiri, M. M., Calle, E. E., Flanders, W. D., Heath C. W., Jr., (1993) Aspirin use and risk of fatal cancer. Cancer Res. 53, 1322-1327.
105. Ratnasinghe, L. D., Graubard, B. I., Kahle, L., Tangrea, J. A., Taylor, P. R., Hawk, E. (2004) Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 24, 3177-3184.
106. Abnet, C. C., Freedman, N. D., Kamangar, F., Leitzmann, M. F., Hollenbeck, A. R., Schatzkin, A. (2009) Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br. J. Cancer 100, 551-557.
107. Epplein, M., Nomura, A. M., Wilkens, L. R., Henderson, B. E., Kolonel, L. N. (2009) Nonsteroidal anti-inflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. Am. J. Epidemiol. 170, 507-515.
108. Cook, N. R., Lee, I. M., Gaziano, J. M., Gordon, D., Ridker, P. M., Manson, J. E., Hennekens, C. H., Buring, J. E. (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294, 47-55.
109. Wong, B. C., Zhang, L., Ma, J. L., Pan, K. F., Li, J. Y., Shen, L., Liu, W. D., Feng, G. S., Zhang, X. D., Li, J., Lu, A. P., Xia, H. H., Lam, S., You, W. C. (2012) Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 61, 812-908.
110. Leung, W. K., Ng, E. K., Chan, F. K., Chan, W. Y., Chan, K. F., Auveung, A. C., Lam, C. C., Lau, J. Y., Sung, J. J. (2006) Effects of longterm rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin. Cancer Res. 12, 4766-4772.
111. Wang, W. H., Huang, J. Q., Zheng, G. F., Lam, S. K., Karlberg, J., Wong, B. C. (2003) Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J. Natl. Cancer Inst. 95, 1784-1791.
112. Yang, P., Zhou, Y., Chen, B., Wan, H. W., Jia, G. Q., Bai, H. L., Wu, X. T. (2010) Aspirin use and the risk of gastric cancer: a meta-analysis. Dig. Dis. Sci. 55, 1533-1539.
113. Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., Meade, T. W. (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet 377, 31-41.
114. Chaturvedi, R., de Sablet, T., Peek, R. M., Wilson, K. T. (2012) Spermine oxidase, a polyamine catabolic enzyme that links Helicobacter pylori CagA and gastric cancer risk. Gut Microbes 3, 48-56.
115. Xu, H., Chaturvedi, R., Cheng, Y., Bussiere, F. I., Asim, M., Yao, M. D., Potosky, D., Meltzer, S. J., Rhee, J. G., Kim, S. S., Moss, S. F., Hacker, A., Wang, Y., Casero R. A., Jr., Wilson, K. T. (2004) Spermine oxidation induced by Helicobacter pylori results in apoptosis and DNA damage: implications for gastric carcinogenesis. Cancer Res. 64, 8521-8525.
116. Chaturvedi, R., Cheng, Y., Asim, M., Bussière, F. I., Xu, H., Gobert, A. P., Hacker, A., Casero R. A., Jr., Wilson, K. T. (2004) Induction of polyamine oxidase 1 by Helicobacter pylori causes macrophage apoptosis by hydrogen peroxide release and mitochondrial membrane depolarization. J. Biol. Chem. 279, 40161-40173.
117. Meyskens F. L., Jr., McLaren, C. E., Pelot, D., Fujikawa-Brooks, S., Carpenter, P. M., Hawk, E., Kelloff, G., Lawson, M. J., Kidao, J., Mc-Cracken, J., Albers, C. G., Ahnen, D. J., Turgeon, D. K., Goldschmid, S., Lance, P., Hagedorn, C. H., Gillen, D. L., Gerner, E. W. (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev. Res. (Phila) 1, 32-38.
118. Haenszel, W., Kurihara, M., Segi, M., Lee, R. K. (1972) Stomach cancer among Japanese in Hawaii. J. Natl. Cancer Inst. 49, 969-988.
119. Peleteiro, B., Lopes, C., Figueiredo, C., Lunet, N. (2011) Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumour site and histological type. Br. J. Cancer 104, 198-207.
120. Wang, X. Q., Terry, P. D., Yan, H. (2009) Review of salt consumption and stomach cancer risk: epidemiological and biological evidence. World J. Gastroenterol. 15, 2204-2213.
121. Cover, T. L., Peek R. M., Jr., (2013) Diet, microbial virulence and Helicobacter pylori-induced gastric cancer. Gut Microbes 4, 482-493.
122. Gaddy, J. A., Radin, J. N., Loh, J. T., Zhang, F., Washington, M. K., Peek R. M., Jr., Algood, H. M., Cover, T. L. (2013) High dietary salt intake exacerbates Helicobacter pylori-induced gastric carcinogenesis. Infect. Immun. 81, 2258-2267.
123. Tsugane, S., Sasazuki, S. (2007) Diet and the risk of gastric cancer: review of epidemiological evidence. Gastric Cancer 10, 75-83.
124. Noto, J. M., Gaddy, J. A., Lee, J. Y., Piazuelo, M. B., Friedman, D. B., Colvin, D. C., Romero-Gallo, J., Suarez, G., Loh, J., Slaughter, J. C., Tan, S., Morgan, D. R., Wilson, K. T., Bravo, L. E., Correa, P., Cover, T. L., Amieva, M. R., Peek R. M., Jr., (2013) Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. J. Clin. Invest. 123, 479-492.
125. Fock, K. M., Katelaris, P., Sugano, K., Ang, T. L., Hunt, R., Talley, N. J., Lam, S. K., Xiao, S. D., Tan, H. J., Wu, C. Y., Jung, H. C., Hoang, B. H., Kachintorn, U., Goh, K. L., Chiba, T., Rani, A. A. (2009) Second Asia-Pacific conference. J. Gastroenterol. Hepatol. 24, 1587-1600.
126. Blaser, M. J. (2005) An endangered species in the stomach. Sci. Am. 292, 38-45.
127. Kamangar, F., Dawsey, S. M., Blaser, M. J., Perez-Perez, G. I., Pietinen, P., Newschaffer, C. J., Abnet, C. C., Albanes, D., Virtamo, J., Taylor, P. R. (2006) Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J. Natl. Cancer Inst. 98, 1445-1452.
128. Eslick, G. D., Lim, L. L., Byles, J. E., Xia, H. H., Talley, N. J. (1999) Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am. J. Gastroenterol. 9, 2373-2379.